110 related articles for article (PubMed ID: 36198130)
1. Cost Study of the PlasmaJet Surgical Device Versus Conventional Cytoreductive Surgery in Patients With Advanced-Stage Ovarian Cancer.
Nieuwenhuyzen-de Boer GM; Geraerds AJLM; van der Linden MH; van Doorn HC; Polinder S; van Beekhuizen HJ
JCO Clin Cancer Inform; 2022 Sep; 6():e2200076. PubMed ID: 36198130
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant Use of PlasmaJet Device During Cytoreductive Surgery for Advanced-Stage Ovarian Cancer: Results of the PlaComOv-study, a Randomized Controlled Trial in The Netherlands.
Nieuwenhuyzen-de Boer GM; Hofhuis W; Reesink-Peters N; Willemsen S; Boere IA; Schoots IG; Piek JMJ; Hofman LN; Beltman JJ; van Driel WJ; Werner HMJ; Baalbergen A; van Haaften-de Jong AMLD; Dorman M; Haans L; Nedelcu I; Ewing-Graham PC; van Beekhuizen HJ
Ann Surg Oncol; 2022 Aug; 29(8):4833-4843. PubMed ID: 35552938
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of effectiveness of the PlasmaJet surgical device in the treatment of advanced stage ovarian cancer (PlaComOv-study): study protocol of a randomized controlled trial in the Netherlands.
Nieuwenhuyzen-de Boer GM; Hofhuis W; Reesink-Peters N; Ewing-Graham PC; Schoots IG; Beltman JJ; Piek JMJ; Baalbergen A; Kooi GS; van Haaften A; van Huisseling H; Haans L; Dorman M; van Beekhuizen HJ
BMC Cancer; 2019 Jan; 19(1):58. PubMed ID: 30642296
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and safety of the PlasmaJet® Device in advanced stage ovarian carcinoma: a systematic review.
Nieuwenhuyzen-de Boer GM; van der Kooy J; van Beekhuizen HJ
J Ovarian Res; 2019 Jul; 12(1):71. PubMed ID: 31362769
[TBL] [Abstract][Full Text] [Related]
5. Cytoreductive Surgery with the PlasmaJet Improved Quality-of-Life for Advanced Stage Ovarian Cancer Patients.
Nieuwenhuyzen-de Boer GM; Aamran H; van den Berg CB; Willemsen S; Piek JMJ; Reesink-Peters N; Maliepaard M; van Doorn HC; Polinder S; van Beekhuizen HJ
Cancers (Basel); 2023 Aug; 15(15):. PubMed ID: 37568763
[TBL] [Abstract][Full Text] [Related]
6. The effects of neutral argon plasma versus electrocoagulation on tissue in advanced-stage ovarian cancer: a case series.
Nieuwenhuyzen-de Boer GM; van de Berg NJ; Gao XS; Ewing-Graham PC; van Beekhuizen HJ
J Ovarian Res; 2022 Dec; 15(1):140. PubMed ID: 36581854
[TBL] [Abstract][Full Text] [Related]
7. The Emerging Role of Neutral Argon Plasma (PlasmaJet) in the Treatment of Advanced Stage Ovarian Cancer: A Systematic Review.
Prodromidou A; Pandraklakis A; Iavazzo C
Surg Innov; 2020 Jun; 27(3):299-306. PubMed ID: 32129144
[No Abstract] [Full Text] [Related]
8. A comparison of the clinical and histological appearances after treatment of advanced stage ovarian cancer with PlasmaJet® device.
Natarajan P; Martha Schofield A; Elena Vinturache A; Ruthven S; Lane S; Duncan Macdonald R
Eur J Obstet Gynecol Reprod Biol; 2024 May; 296():311-315. PubMed ID: 38518485
[TBL] [Abstract][Full Text] [Related]
9. Cost Effectiveness of Interval Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy in Stage III Ovarian Cancer on the Basis of a Randomized Phase III Trial.
Koole SN; van Lieshout C; van Driel WJ; van Schagen E; Sikorska K; Kieffer JM; Schagen van Leeuwen JH; Schreuder HWR; Hermans RH; de Hingh IH; van der Velden J; Arts HJ; Massuger LFAG; Aalbers AG; Verwaal VJ; Van de Vijver KK; Aaronson NK; van Tinteren H; Sonke GS; van Harten WH; Retèl VP
J Clin Oncol; 2019 Aug; 37(23):2041-2050. PubMed ID: 31251694
[TBL] [Abstract][Full Text] [Related]
10. Clinical implementation of routine diagnostic laparoscopy to guide initial treatment in patients with advanced-stage epithelial ovarian cancer in Dutch clinical practice: Evaluation of support and a budget impact analysis.
Lof P; Retèl VP; Algera MD; van Gent MDJM; Gaarenstroom KN; van Driel WJ
Gynecol Oncol; 2022 Jun; 165(3):459-465. PubMed ID: 35414427
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of laparoscopy as diagnostic tool before primary cytoreductive surgery in ovarian cancer.
van de Vrie R; van Meurs HS; Rutten MJ; Naaktgeboren CA; Opmeer BC; Gaarenstroom KN; van Gorp T; Ter Brugge HG; Hofhuis W; Schreuder HWR; Arts HJG; Zusterzeel PLM; Pijnenborg JMA; van Haaften M; Engelen MJA; Boss EA; Vos MC; Gerestein KG; Schutter EMJ; Kenter GG; Bossuyt PMM; Mol BW; Buist MR
Gynecol Oncol; 2017 Sep; 146(3):449-456. PubMed ID: 28645428
[TBL] [Abstract][Full Text] [Related]
12. Upfront cytoreductive surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer in Indian patients.
Ray MD; Deo SSV; Kumar L; Gaur MK
Future Oncol; 2021 Sep; 17(27):3607-3614. PubMed ID: 34263662
[TBL] [Abstract][Full Text] [Related]
13. ASO Author Reflections: The PlasmaJet
Nieuwenhuyzen-de Boer GM; van Beekhuizen HJ
Ann Surg Oncol; 2022 Aug; 29(8):4844-4845. PubMed ID: 35482266
[No Abstract] [Full Text] [Related]
14. Use of PlasmaJet for Peritoneal Carcinomatosis in Ovarian Cancer.
Panuccio E; Leunen K; Van Nieuwenhuysen E; Neven P; Lambrechts S; Vergote I
Int J Gynecol Cancer; 2016 Oct; 26(8):1521-4. PubMed ID: 27488213
[TBL] [Abstract][Full Text] [Related]
15. Textbook outcome as a composite outcome measure to compare hospital performances regarding cytoreductive surgery for ovarian cancer: A nationwide population-based study.
Algera MD; Slangen BFM; van Driel WJ; Wouters MWJM; Kruitwagen RFPM;
Gynecol Oncol; 2023 Jul; 174():89-97. PubMed ID: 37167897
[TBL] [Abstract][Full Text] [Related]
16. Primary debulking surgery of the upper abdomen and the diaphragm, with a plasma device surgery system, for advanced ovarian cancer.
Cordeiro Vidal G; Babin G; Querleu D; Guyon F
Gynecol Oncol; 2017 Jan; 144(1):223-224. PubMed ID: 27836207
[TBL] [Abstract][Full Text] [Related]
17. Incorporating robotic surgery into the management of ovarian cancer after neoadjuvant chemotherapy.
Abitbol J; Gotlieb W; Zeng Z; Ramanakumar A; Kessous R; Kogan L; Pare-Miron V; Rombaldi M; Salvador S; Kucukyazici B; Brin S; How J; Lau S
Int J Gynecol Cancer; 2019 Nov; 29(9):1341-1347. PubMed ID: 31601648
[TBL] [Abstract][Full Text] [Related]
18. [Technical essentials and safety analysis of "rolling carpet" cytoreduction surgery in stage Ⅲc epithelial ovarian cancer].
Liu H; Shi Y; Zhang GN; Yu J; Xu SQ; Wang DF; Fan Y; Song SQ; Zhou FZ
Zhonghua Fu Chan Ke Za Zhi; 2020 Aug; 55(8):521-528. PubMed ID: 32854476
[No Abstract] [Full Text] [Related]
19. Critical Analysis of Stage IV Epithelial Ovarian Cancer Patients after Treatment with Neoadjuvant Chemotherapy followed by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC).
Munoz-Zuluaga CA; Sardi A; Sittig M; Gushchin V; King MC; Nieroda C; Lopez-Ramirez F; Diaz-Montes TP
Int J Surg Oncol; 2020; 2020():1467403. PubMed ID: 33381312
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer.
Coleridge SL; Bryant A; Kehoe S; Morrison J
Cochrane Database Syst Rev; 2021 Jul; 7(7):CD005343. PubMed ID: 34328210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
